Research
Hormonal
Weight loss under Semaglutid therapy can be comparable to bariatric surgical intervention.
Semaglutid may be a viable alternative for patients who are not candidates for surgery.
StrongSupportsmedium confidence
Die Gewichtsreduktion unter dieser Therapie ist teils schon mit bariatrisch-chirurgischer Intervention vergleichbar.
Why this rating
The claim is based on comparative effectiveness stated in the abstract.
Source
Adipositas – eine behandlungsbedürftige chronische Erkrankung
Svenja Meyhöfer et al. · DMW - Deutsche Medizinische Wochenschrift · 2022
DOI 10.1055/a-1657-2047
otherCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →